Diagnose and Treat with Answers
Melanoma Skin cancer
Studies have shown that early and accurate diagnosis of melanoma is critical for long-term survival.1 Myriad offers a test that can be used with histopathology when the distinction between benign nevus and malignant melanoma cannot be made confidently by pathology alone.
Patient care begins with knowledge and your patients deserve accurate and actionable test results that you trust.
Myriad Oncology's Tests for Melanoma Cancer and What Answers They Provide:
23-Gene expression test - to assist with diagnosing melanoma when pathology alone is unclear
myPath Melanoma® is a validated diagnostic molecular test that differentiates nevi from melanoma in challenging cases. By measuring the expression of 23 genes, myPath Melanoma produces an easy-to-interpret score classified as benign, malignant, or indeterminate.
Hereditary cancer testing
The Myriad myRisk® test is a 35-gene cancer panel that will provide appropriate patients with melanoma information on:
- Whether their case of melanoma is hereditary (or caused by a genetic mutation)
- Their risk of developing other cancers – Having certain genetic mutations puts patients at a higher risk of developing additional cancers than the general public.
- Potential surgical considerations and treatment eligibility
- Potential hereditary cancer risk for their family members – Knowing mutation status provides the opportunity for family members to take proactive screening and/or preventative measures if appropriate.
Certain mutations can leave individuals with a lifetime risk of developing hereditary melanoma of up to 76%2
By incorporating leading medical society guidelines into the results through our myRisk Medical Management Tool, myRisk can provide comprehensive information about your patient’s unique cancer. Using industry leading accuracy, unmatched turnaround time, and a lifetime commitment to patients, myRisk should be a part of cancer workups.
- Data is adapted from information found at: www.cancer.org/cancer/ skincancer-melanoma/detailedguide/melanoma-skin-cancer-survival-rates
- Begg CB, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005 Oct 19;97(20):1507-15.